BIOTECH
Five Hurdles for Biotech
The science is hot and the stocks are up. Here's what's needed to deliver on the promise
1) Decode the Causes of Diseases
2) Free the Flow of Information
3) Craft Smarter Regulations
4) Explore New Modes of Manufacturing
5) Sustain Investors' Confidence
Putting Bioterror on the Front Burner
America's arsenal of vaccines and drugs is inadequate, but the biotech industry is starting to fill the void
Online Extra: Craig Venter: Beyond "Bio-Babble"
The gene-decoding whiz explains why the common notion that genetic discoveries lead directly to drug breakthroughs is wrong
Online Extra: Thomas Okarma: Don't Ban Stem-Cell Research
Geron's CEO on the "disaster" of the federal funding cutoff for new embryonic stem-cell lines and the confusion over "cloning"
Online Extra: Roger Perlmutter: Teamwork Is Key
Amgen's lead researcher says "individual scientists view themselves as artists," but they'll have to learn to work together
Online Extra: Hunting the Genes of Mental Illness
The two leaders of Psychiatric Genomics explain their quest to fathom the genetic basis of manic depression, autism, and schizophrenia
Online Extra: The Right Doctor for the FDA?
New chief Mark McClellan is moving decisively to get the agency's new-drug approvals speeded up -- to the industry's delight
Online Extra: New Life for Genomics Stocks
The sector got hit hard, once investors realized these companies wouldn't produce quick hits. Now, some survivors look attractive
| |
SAM STOVALL'S SECTOR WATCH
Where to Bet on the Biotech Breakout
S&P's industry analyst expects the good times to keep rolling -- for
selected, profitable companies with solid prospects
(5/21/03)
INVESTING Q&A
Big Pharma's Pick-Me-Up: A Down Dollar
S&P's Herman Saftlas is upbeat about a brace of drug stocks, while
colleague Frank DiLorenzo sees smaller gains for biotechs
(5/16/03)
THE BIOTECH BEAT
Using Teamwork to Tackle Disease
DNA research pioneer Dr. Leroy Hood is now assembling a group of experts
in different scientific fields to investigate "systems biology"
(4/24/03)
THE BIOTECH BEAT
Biogen: No More One-Hit Wonder?
CEO James Mullen talks about Amevive, the new psoriasis treatment that
could be the first step to a diversified product line (3/6/03)
INSIDE WALL STREET ONLINE
Biotechs That Could Break from the Pack
Merrill Lynch's Eric Ende pinpoints four with accelerating earnings and
improving fundamentals: Amgen, MedImmune, Gilead, and NPS (1/7/03)
THE BIOTECH BEAT
HGS's Haseltine: "We're Batting .800"
A giant of the biotech industry says his company's genomic approach to
developing drugs sets it apart from the pack (2/28/03)
|
=Subscribers Only
Copyright 2003, Bloomberg L.P.
